Sepsis is a syndrome, a consequence of an overwhelming systemic response to infection. It rapidly leads to organ dysfunction, which accompanies systemic inflammation and hematological abnormalities. In Gram-negative bacteria, lipopolysaccharide (LPS) has a dominant role for the activation of various cells, which secrete several proinflammatory cytokines including TNF-α. These cytokines are also important in inducing a procoagulant effect in sepsis. On the other hand, toll-like receptor 4 (TLR4) is responsible for the LPS signaling and causes the activation of NF-κB. It is clear that an inappropriate TLR response to bacterial infection could have critical consequences. Therefore, TLR4 signal inhibitor is attractive as a therapeutic medication for sepsis.

The benzisothiazole derivative (M62812) was found as a TLR4 signal transduction inhibitor using the reporter gene assay system. It also suppressed LPS-induced upregulation of proinflammatory cytokines, adhesion molecules and procoagulant activity in human vascular endothelial cells and/or peripheral mononuclear cells. The half-maximal inhibitory concentrations (IC~50~) of this compound in these assays were ranging from 1 to 3 μg/ml. Single intravenous administration of M62812 (10 mg/kg) protected mice from death in murine [D]{.smallcaps}-galactosamine-sensitized endotoxin shock model (Table [1](#T1){ref-type="table"}). In this model, M62812 (20 mg/kg) completely improved the elevation of inflammatory cytokines and the hematological abnormalities. Furthermore, M62812 (20 mg/kg) also prevented mice from the lethal shock in murine cecal ligation and puncture model.

  Group              Survival rate (%)
  ------------------ -------------------
  M62812, 5 mg/kg    0
  M62812, 10 mg/kg   50
  M62812, 20 mg/kg   90

LPS is a potent and predominant microbial mediator that induces an intense inflammation and procoagulant response, which are closely correlated events. M62812 inhibits those responses *in vitro*and prevents lethal shock in animal models. Therefore, we concluded that it will become a novel therapeutic medication for sepsis and septic shock by inhibiting TLR4 signal transduction and improving endothelial cell and leukocyte cell functions.
